SCHEMBL2958644

SCHEMBL2958644

Cc1ccc(-n2c(=O)ccc3c(Nc4cccc(C)c4)c(C(N)=O)sc32)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 3/20 0.39
MAPT P10636 7/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GFER P55789 1/20 0.39
CSF1R P07333 1/20 0.38
NPC1 O15118 2/20 0.37
RXFP1 Q9HBX9 2/20 0.37
PSMD14 O00487 1/20 0.37
POLB P06746 1/20 0.37
MMP2 P08253 1/20 0.37
PTPN7 P35236 1/20 0.37
PPARG P37231 1/20 0.37
DUSP3 P51452 1/20 0.37
PTPN5 P54829 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2956387 0.94 MAPT (0.43) RAB9ASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL2949616 0.93 DRD4 (0.40) RAB9ASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL2952347 0.91 IDO1 (0.40) RAB9ASMN1; SMN2KDM4EMAPTCSF1R
SCHEMBL2956424 0.86 CHRNA7 (0.39) RAB9ASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL2950317 0.85 CSF1R (0.39) SMN1; SMN2MAPTALDH1A1HPGDAPOBEC3G
SCHEMBL2958459 0.85 MAPT (0.41) RAB9ASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL2949768 0.85 MAPT (0.41) RAB9ASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL2949780 0.84 MAPT (0.47) RAB9ASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL2955772 0.83 CYP3A4 (0.39) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL2958575 0.82 CDK4 (0.38) RAB9ASMN1; SMN2KDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK RAB9A 3150/4885SMN1; SMN2 3637/4885KDM4E 2174/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 RAB9A 2791/4885SMN1; SMN2 3472/4885KDM4E 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.